Author, year, country | Last search date | Disease | H2RAs | PPI | No. of studies in MA | No. of patients in MA | Eradication rates by ITT | Eradication rates odds ratio (95 % CI) by ITT | Quality assessmenta |
---|---|---|---|---|---|---|---|---|---|
Gisbert et al. 2003 Spain [40] | Jan 2002 | HP infection; naïve to treatment; PUD/NUD | H2RAs (ranitidine/famotidine/nizatidine)+ | PPI (ome/lanso)+ | 20 | 2374 | 69 % vs. 74 % | Triple vs. H 2 RAs 1.31 (1.09-1.58) | + |
+ two same antibiotics (amoxicillin/clarithromycin/metronidazole/tinidazole) +/− bismuth- | |||||||||
Graham et al. 2003 US [53] | 1990–2001 (Published date) | HP infection; either naïve or with previous treatment failures | H2RAs(nizatidine/famotidine/ranitidine) + | PPI (lanso/ome) + | 12 | 1441 | 78 % vs. 81 % | 0.83 (0.63–1.09) | 0 |
+ two same antibiotics (clarithromycin/amoxicillin/metronidazole/tinidazole) | |||||||||
H2RAs(not specified)+ | Clarithromycin-containing triple : Clarithromycin + PPI(not specified)+ | 6 | Not reported | 79 % vs. 69 % | 1.14 (0.76–1.71) | ||||
+ one same antibiotics (not specified) | |||||||||
H2RAs(not specified)+ | Clarithromycin NOT-containing triple: PPI(not specified)+ | 6 | Not reported | 78 % vs. 85 % | 0.64 (0.45–0.92) | ||||
+two same antibiotics (not specified) | |||||||||
Ren et al. 2010 China [41] | Apr 2010 | HP infection; naïve to treatment | Lafutidine-containing: H2RAs(lafutidine)+ | Lanso-containing triple: PPI(lanso) + | 3 | 238 | 78 % vs. 77.5 % | 1.03 (0.64–1.66) | ++ |
+ two same antibiotics (clarithromycin + amoxicillin) |